Clinical trial
GW572016 In Patients With Advanced Or Metastatic Breast Cancer
NCT00462956 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00462956 |
|---|---|
| Title | GW572016 In Patients With Advanced Or Metastatic Breast Cancer |
| Official title | Phase II Clinical Study of GW572016 in Patients With Advanced or Metastatic Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Tykerb |
| Enrollment | 59 |
| Start date | Jun 30, 2004 |
| Primary completion | Dec 20, 2006 |
| Completion | Dec 20, 2006 |
| First posted | Apr 19, 2007 |
| Last update posted | Aug 31, 2018 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: